{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-25-001591","form_type":"8-K","ticker":"AVXL","cik":"0001314052","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2025-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.064921+00:00","generated_at":"2026-05-16T16:51:04.049550+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Anavex Life Sciences Reports Fiscal 2025 Q4 Net Loss of $9.8M and CHMP Negative Vote for Blarcamesine","bullets":["Net loss for Q4 fiscal 2025 was $9.8M ($0.11 per share), compared to net loss of $11.6M ($0.14) in Q4 fiscal 2024.","Cash and cash equivalents were $102.6M at September 30, 2025, down from $132.2M a year ago; current cash over $120M with >3 year runway.","CHMP of EMA issued a negative trend vote on the Marketing Authorisation Application for blarcamesine; Anavex intends to request re-examination.","Positive topline results from Phase 2 study of ANAVEX3-71 for schizophrenia: safe and well-tolerated, primary safety endpoint met.","Research & development expenses for the quarter were $7.3M, down from $11.6M in the prior year quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-25-001591","json":"https://secwatch.observer/filing/0001731122-25-001591.json","markdown":"https://secwatch.observer/filing/0001731122-25-001591.md","text":"https://secwatch.observer/filing/0001731122-25-001591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225001591/0001731122-25-001591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225001591/e7068_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T16:51:04.049550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}